Verismo Therapeutics Showcases Promising Preclinical Results for SynKIR™-110 CAR Therapy at SITC 2026

Verismo Therapeutics recently unveiled groundbreaking preclinical findings on their innovative SynKIR™-110 KIR-CAR therapy at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting held in Phoenix, Arizona. This dynamic company, which is making strides in the field of CAR T cell therapies, presented compelling data that underscores its potential to significantly enhance anti-tumor activity while minimizing cytokine release, thus advancing the safety profile of CAR therapies.

Enhanced Tumor Control and Safety Profile

In preclinical trials, SynKIR™-110 exhibited an impressive capability to expedite tumor control, achieving outcomes far superior to traditional CAR T designs. Notably, it produced cytokine levels that were approximately ten times lower in terms of interferon-gamma (IFNγ) and thirty times lower for TNF-alpha and IL-2 when compared to CD28-based single-chain CAR T cells. These findings illustrate how SynKIR™-110 not only targets cancer more effectively but does so with lesser side effects—a crucial development for patient safety and treatment effectiveness.

The research team behind this discovery utilized mesothelioma xenograft models to compare SynKIR™-110 with other CAR options. The results were striking: tumor-infiltrating CD8+ T cells utilizing SynKIR™-110 displayed lower markers of exhaustion, such as TIM3, LAG3, and PD1, compared to the conventional single-chain CAR T cells. In contrast to these comparators, SynKIR™-110 did not lead to detrimental accumulation of T cells in healthy lung tissue during in vivo assessments, a significant concern associated with existing CAR therapies.

Mechanistic Advances

Dr. Laura Johnson, Chief Scientific Officer and COO of Verismo Therapeutics, remarked on the implications of these findings. She explained that the success of SynKIR™-110 stems from its unique multi-chain KIR-CAR architecture. By separating the processes of antigen binding from T cell activation, this approach effectively reduces unwanted off-target activity and mitigates non-specific signaling that has traditionally complicated CAR T therapies. This refined mechanism carries the potential to transform how cancer is treated, particularly in patients who previously struggled to benefit from existing CAR strategies.

Innovative Clinical Trials and Designations

Currently, SynKIR™-110 is undergoing evaluation in the Phase 1 STAR-101 clinical trial targeted at patients with advanced solid tumors that express mesothelin, including conditions like mesothelioma and ovarian cancer. Initial results from a recent presentation at the American Association for Cancer Research (AACR) 2026 have shown an encouraging safety profile with no observed dose-limiting toxicities or severe cytokine release syndrome. Furthermore, tumor reduction was noted, marking a positive trajectory for this innovative therapy.

Verismo Therapeutics is not only advancing patient care with the development of SynKIR™, but has also received Orphan Drug and Fast Track designations from the U.S. FDA, prioritizing this therapy for mesothelioma treatment. As the ongoing clinical trials continue, the company seeks to establish dosage recommendations for future applications, aiming for efficacy across challenging tumor profiles.

A New Dawn for CAR T Therapy

In summary, Verismo Therapeutics stands at the forefront of CAR T cell therapy innovations with its KIR-CAR platform, which shows promise in addressing critical medical needs in oncology. With an approach that balances efficacy and safety, SynKIR™-110 is paving the way for future advancements in cancer treatment methodologies. It’s a significant step towards not only better management of solid tumors but also a beacon of hope for patients facing tough battles against cancer. As research progresses, the oncology community eagerly anticipates the next phases of development for SynKIR™-110 and looks forward to its potential broader applications across various malignancies.

For more updates, visit Verismo Therapeutics for the latest news and advancements in KIR-CAR technology.